Kymera Therapeutics (KYMR) net assets (shareholders' equity)

Net assets · fiscal 2025
$1.58B

Kymera Therapeutics (KYMR) had net assets of $1.58B at the end of fiscal 2025 (December 31, 2025). That is 89.0% higher than the $835.62M of fiscal 2024. Figures as of 18 Nov 2026, 23:47 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Net assets, fiscal 2025
$1.58B
Change on fiscal 2024
+89.0%
Growth, 5 years
+41.0% a year
Highest on record
$1.58Bfiscal 2025
Lowest on record
-$74.41Mfiscal 2019
Fiscal years on record
72019–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Kymera Therapeutics net assets (shareholders' equity), in more detail

Over the five fiscal years to 2025 net assets grew at a compound 41.0% a year. Across the 7 fiscal years on record (2019–2025), the highest was $1.58B in fiscal 2025 and the lowest -$74.41M in fiscal 2019.

History · 7 fiscal years

Net assets by fiscal year

Kymera Therapeutics net assets (shareholders' equity), year by year

Kymera Therapeutics (KYMR) net assets (shareholders' equity) by fiscal year
Fiscal yearNet assetsChangeYear ended
2025$1.58B 89.0% up
2024$835.62M 111.6% up
2023$394.97M 19.4% down
2022$490.15M 6.6% up
2021$459.64M 61.9% up
2020$283.89M—
2019-$74.41M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

Net assets at health care companies of similar size

Net assets of Kymera Therapeutics and comparable companies
CompanyNet assetsFiscal year
Fresenius Medical Care FMS€13.31B2025
Kymera Therapeutics KYMR$1.58B2025
DaVita DVA-$651.08M2025
Halozyme Therapeutics HALO$48.81M2025
Universal Health Services UHS$7.28B2025
Repligen RGEN$2.11B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on KYMR

Kymera Therapeutics, figure by figure

Kymera Therapeutics (KYMR) overview: price, valuation and scorecardAll health care companies by market value

Kymera Therapeutics net assets (shareholders' equity): questions and answers

What are Kymera Therapeutics's net assets?

Kymera Therapeutics (KYMR) had net assets of $1.58B at the end of fiscal 2025 (December 31, 2025). That is 89.0% higher than the $835.62M of fiscal 2024.

What is the growth rate of Kymera Therapeutics's net assets?

Over the five fiscal years to 2025 net assets grew at a compound 41.0% a year.

What are the highest and lowest net assets figures on record for Kymera Therapeutics?

Across the 7 fiscal years on record (2019–2025), the highest was $1.58B in fiscal 2025 and the lowest -$74.41M in fiscal 2019.

How is Kymera Therapeutics's net assets calculated?

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Kymera Therapeutics it is on record here for 7 fiscal years, 2019 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Kymera Therapeutics (KYMR) net assets (shareholders' equity)”, data as of 18 November 2026. https://funkfolio.com/stock/KYMR/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.